Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
X4 Pharmaceuticals appointed Kelly Gold as a Class II director effective July 1, 2026, expanding its board from five to six members. She will serve as an independent director and join the Board’s Audit Committee.
Gold is currently Chief Financial Officer of CAMP4 Therapeutics and previously held senior finance and corporate development roles at CAMP4 and Biogen, as well as investment banking roles at Deutsche Bank. She holds dual bachelor’s degrees in life sciences and mechanical engineering from Queen’s University and an MBA from MIT Sloan. X4 highlights her financial leadership, capital markets experience and scientific background as aligned with its focus on rare hematology diseases and the continued development of mavorixafor, which is approved in the U.S. and EU as XOLREMDI for WHIM syndrome.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size after appointment: 6 directors
Kelly Gold age: 49 years
Effective date: July 1, 2026
+1 more
4 metrics
Board size after appointment
6 directors
Board increased from five to six with Kelly Gold’s appointment
Kelly Gold age
49 years
Age of newly appointed Class II director
Effective date
July 1, 2026
Effective date of Kelly Gold’s board and Audit Committee roles
CAMP4 CFO tenure start
April 2022
Start of Kelly Gold’s role as Chief Financial Officer at CAMP4
Key Terms
Class II director, independent director, Audit Committee, Fast Track designation, +1 more
5 terms
Class II director regulatory
"appointed Kelly Gold as a Class II director of the Company"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
independent director regulatory
"Ms. Gold will serve as an independent director and member of the Audit Committee"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Audit Committee financial
"Ms. Gold has also been appointed to serve on the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Fast Track designation regulatory
"The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
Phase 3 clinical trial medical
"currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor"
A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | | ||||
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 30, 2026
| (Exact name of registrant as specified in its charter) | ||||||||
| | ||||||||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
(857) 529-8300
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
_______________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | ||||
On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026. In connection with Ms. Gold’s appointment, the size of the Company’s board of directors (the “Board”) was increased from five to six directors. Ms. Gold has also been appointed to serve on the Audit Committee of the Board.
Ms. Gold, age 49, has served as Chief Financial Officer of CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company (Nasdaq: CAMP), since April 2022. Ms. Gold previously served as CAMP4’s Chief Business Officer from April 2021 to March 2022, and held positions of increasing responsibility in Finance and Corporate Development at CAMP4 from 2017 to March 2021. Ms. Gold previously served as Associate Director, Strategic Corporate Finance at Biogen Inc. (Nasdaq: BIIB) from 2014 to 2017, where she provided financial leadership for the company’s late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization. Ms. Gold also previously served as a Healthcare Investment Banking Associate at Deutsche Bank from 2009 to 2013, where she worked in the healthcare investment banking group. Ms. Gold earned bachelor’s degrees in Life Sciences and Mechanical Engineering from Queen’s University in Ontario and an MBA from the MIT Sloan School of Management.
In connection with her appointment to the Board, Ms. Gold will be entitled to receive compensation in accordance with the Company’s non-employee director compensation policy as generally described in the Company’s Definitive Proxy Statement filed on March 20, 2026. Ms. Gold is also entering into the Company’s standard form of indemnification agreement, a form of which was previously filed as Exhibit 10.36 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed on November 6, 2017.
There are no arrangements or understandings between Ms. Gold and any other person pursuant to which she was appointed as director of the Company; there are no family relationships between Ms. Gold and any director or executive officer of the Company; and Ms. Gold is not a party to any transactions of the type that would require disclosure under Item 404(a) of Regulation S-K.
| Item 7.01 | Regulation FD Disclosure. | ||||
A copy of the Company’s press release announcing the foregoing appointment is furnished hereto as Exhibit 99.1.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. | ||||
(d) Exhibits. The following exhibits are being furnished herewith:
| Exhibit Number | Exhibit Title or Description | |||||||
| 99.1 | Press Release, dated July 1, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| X4 PHARMACEUTICALS, INC. | |||||||||||
| By: | /s/ David Kirske | ||||||||||
| David Kirske | |||||||||||
| Date: July 1, 2026 | Chief Financial Officer and Treasurer | ||||||||||
Exhibit 99.1
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
BOSTON, July 1, 2026 – X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee.
“We are thrilled to welcome Kelly to our Board of Directors as she brings a distinct combination of financial leadership, capital markets expertise and a scientific background,” said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. “As we continue to strengthen our team to align with our strategic priorities, Kelly’s experience as a public company CFO, coupled with her deep understanding of the biotech landscape will be a great addition to our Board. We look forward to leveraging her experience as we continue to progress mavorixafor towards potential approval and commercialization.”
"I am honored to join X4 Pharmaceuticals’ Board at this important stage in the company's evolution. X4 has built a strong foundation through its commitment to developing innovative therapies for patients living with rare diseases, and I look forward to working alongside my fellow directors and the leadership team as the company advances its mission," added Ms. Gold.
Ms. Gold is currently the Chief Financial Officer at CAMP4 Therapeutics (Nasdaq: CAMP) where she has held roles of increasing responsibility leading the Business Development and Finance functions before becoming CFO. At CAMP4, she leads all corporate finance and accounting, investor relations, strategic financial planning, and is responsible for guiding and executing the company’s strategy for establishing innovative strategic and technology-based partnerships. Previously, Ms. Gold held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late stage and marketed rare disease programs and developed long-term strategic financial trajectories for the R&D organization. Prior to Biogen, Ms. Gold worked in the Healthcare and Latin American Investment Banking groups at Deutsche Bank. Ms. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities. She holds bachelor’s degrees in
Biochemistry and Mechanical Engineering from Queen’s University in Ontario, as well as an MBA from the MIT Sloan School of Management.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com
Source: X4 Pharmaceuticals, Inc.
FAQ
What did X4 Pharmaceuticals (XFOR) announce in this 8-K filing?
X4 Pharmaceuticals announced the appointment of Kelly Gold as a Class II independent director, effective July 1, 2026, and her addition to the Audit Committee. The filing also furnishes a press release describing her background and reiterating X4’s focus on rare hematology diseases and mavorixafor.
Who is Kelly Gold and what is her background relevant to X4 Pharmaceuticals (XFOR)?
Kelly Gold is the Chief Financial Officer of CAMP4 Therapeutics and a former Biogen finance leader and Deutsche Bank investment banker. She brings experience in corporate finance, capital markets, rare disease programs, and strategic partnerships, plus technical training in biochemistry and mechanical engineering and an MBA from MIT Sloan.
How does Kelly Gold’s appointment change X4 Pharmaceuticals’ (XFOR) board structure?
Kelly Gold’s appointment increases X4 Pharmaceuticals’ board size from five to six directors and adds another independent member to the Audit Committee. The company describes her as bringing strong strategic and financial expertise that supports its governance as it advances its rare disease portfolio.
What is X4 Pharmaceuticals’ lead therapy mavorixafor and its current status?
Mavorixafor is an orally available CXCR4 antagonist developed by X4 Pharmaceuticals for rare hematology diseases. It is approved in the U.S. and EU as XOLREMDI for patients with WHIM syndrome, and is being evaluated in a global pivotal Phase 3 trial for chronic neutropenic disorders.
What regulatory designations has mavorixafor received according to X4 Pharmaceuticals (XFOR)?
The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. Fast Track status is intended to facilitate development and expedite review of therapies for serious conditions, reflecting recognition of potential benefit in that setting.
Does this 8-K filing disclose any financial results for X4 Pharmaceuticals (XFOR)?
This filing focuses on governance and leadership, specifically the appointment of Kelly Gold to the board and Audit Committee. It does not present financial results or earnings data, instead emphasizing board composition and the company’s ongoing efforts around its rare hematology pipeline.